One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

WeDosify becomes CLM’s first commercially available product – delivering data-driven, adaptive dosing recommendations to improve GLP-1 adherence.Informed by 29 studies and 15,000+ patient profiles; ...

Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...

Earlier in 2025, UNSW Sydney Ph.D. candidate Christina Schmidt submitted her thesis—from the deck of Australia's ...

Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded. [Operator Instructions] As a reminder, this conference is being recorded. It is now my ...

Working together as a team to better communicate between physicians and nurses as well as the complete caregiving team will ...

In The Lancet Diabetes & Endocrinology, the STEP-UP T2D and STEP-UP trial groups present new findings on the efficacy and safety of higher-dose semaglutide (7·2 mg once weekly) in individuals with ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

By seeing yourself with grace, you create an internal safe space where you can grow. You can love your shadow and feel unconditional love, When you have your own back, you’ll feel braver to take the ...